Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
The current Biogen(BIIB) stock price is $186.79, with a market capitalization of 27.58B. The stock trades at a price-to-earnings (P/E) ratio of 20.07.
During the trading session on 2026-05-04, Biogen(BIIB) shares reached a daily high of $187.41 and a low of $185.44. At a current price of $186.79, the stock is +0.7% higher than the low and still -0.3% under the high.
Trading volume for Biogen(BIIB) stock has reached 273.06K, versus its average volume of 1.25M.
The stock's 52-week range extends from a low of $115.25 to a high of $202.41.
The stock's 52-week range extends from a low of $115.25 to a high of $202.41.
BIIB News
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
In April 2026, Biogen Inc. reported first-quarter 2026 results showing revenue of US$2.48 billion and net income of US$319.5 million, with earnings per share ri...
Freedom Broker analyst Ilya Zubkov upgraded Biogen (BIIB) to Buy from Hold with a price target of $245, up from $185. The firm views the company’s acquisition o...
Analyst ratings
53%
of 38 ratingsMore BIIB News
Biogen (BIIB) is back in focus after recent trading left the stock around $189.28, with returns over the past month and past 3 months contrasting with a weaker...
Biogen (NASDAQ:BIIB) reported upbeat earnings for the first quarter on Wednesday. The company posted quarterly earnings of $3.57 per share which beat the analy...
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Biogen and keeping the price target at $196.00. Claim 55% Off TipRanks Unlock hedge fund-lev...
Wedbush raised the firm’s price target on Biogen (BIIB) to $196 from $191 and keeps a Neutral rating on the shares. While the firm anticipated Q1 would likely b...
Phil Nadeau, an analyst from TD Cowen, assigned the Buy rating on Biogen. The associated price target is $215.00. Unlock hedge fund-level data and powerful inv...
Biogen Inc. ((BIIB)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and powerfu...
Key Points The company continues to pivot away from its traditional strength in multiple sclerosis treatments. Its recent acquisition of Apellis Pharmaceutica...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.